Tamoxifen Tablets

[10 March 2015]

Products Affected - Description

Tamoxifen tablets, Mylan
10 mg, 500 count (NDC 00378-0144-05) - discontinued
20 mg, 100 count (NDC 00378-0274-01) - discontinued
Tamoxifen tablets, Teva
20 mg, 500 count (NDC 00093-0782-05)
20 mg, 1000 count (NDC 00093-0782-10)

Reason for the Shortage

  • Teva could not provide a reason for the shortage.
  • Mylan discontinued tamoxifen 10 mg 500 count and 20 mg 100 count presentations.
  • Actavis could not provide a reason for the shortage.

Available Products

Tamoxifen tablets, Actavis
10 mg, 60 count (NDC 00591-2472-60)
10 mg, 180 count (NDC 00591-2472-18)
20 mg, 30 count (NDC 00591-2473-30)
20 mg, 90 count (NDC 00591-2473-19)
Tamoxifen tablets, Mylan
10 mg, 60 count (NDC 00378-0144-91)
20 mg, 30 count (NDC 00378-0274-93)
Tamoxifen tablets, Teva
10 mg, 60 count (NDC 00093-0784-06)
10 mg, 180 count (NDC 00093-0784-86)
10 mg, 500 count (NDC 00093-0784-05)
10 mg, 1000 count (NDC 00093-0784-10)
20 mg, 30 count (NDC 00093-0782-56)
20 mg, 100 count (NDC 00093-0782-01)

Estimated Resupply Dates

Teva has tamoxifen 20 mg tablets in 500 and 1000 count sizes on back order and the company estimates a release date of early-May 2015.

Related Shortages


March 10, January 7, 2015; October 22, August 4, May 9 and 29, April 3 and 15, March 6, January 7, 2014, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.